UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2019
or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Commission File Number: 000-54500
Cell MedX Corp.
(Exact name of registrant as specified in its charter)
|
Nevada |
|
38-3939625 |
|
(State or other jurisdiction of |
|
(I.R.S. Employer |
|
incorporation or organization) |
|
Identification No.) |
|
123 W. Nye Ln, Suite 446 Carson City, NV |
|
89706 |
|
(Address of principal executive offices) |
|
(Zip code) |
(844) 238-2692
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer [ ] |
|
Accelerated filer [ ] |
|
Non-accelerated filer [ ] |
|
Smaller Reporting Company [X] |
|
|
|
Emerging Growth Company [ ] |
Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.) Yes [ ] No [X]
The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of January 14, 2020 was 55,815,709.
CONTENTS
ii
PART I - FINANCIAL INFORMATION
The accompanying unaudited consolidated interim financial statements of Cell MedX Corp. as at November 30, 2019, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.
Operating results for the three and six months ended November 30, 2019, are not necessarily indicative of the results that can be expected for the year ending May 31, 2020.
As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.
1
CELL MEDX CORP.
CONSOLIDATED BALANCE SHEETS
(EXPRESSED IN US DOLLARS)
(Unaudited)
The accompanying notes are an integral part of these interim consolidated financial statements.
F-2
CELL MEDX CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(EXPRESSED IN US DOLLARS)
(Unaudited)
|
|
|
Three Months Ended November 30, |
|
Six Months Ended November 30, |
||||||
|
|
|
2019 |
2018 |
|
2019 |
2018 |
||||
|
|
|
|
|
|
|
|
||||
|
Revenue |
|
|
|
|
|
|
||||
|
Sales |
|
$ |
757 |
$ |
- |
|
$ |
12,100 |
$ |
- |
|
Distribution rights |
|
|
9,480 |
|
- |
|
|
18,438 |
|
- |
|
Cost of goods sold |
|
|
522 |
|
- |
|
|
5,897 |
|
- |
|
Gross margin |
|
|
9,715 |
|
- |
|
|
24,641 |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
Amortization |
|
|
545 |
|
110 |
|
|
813 |
|
110 |
|
Consulting fees |
|
|
61,728 |
|
66,678 |
|
|
150,999 |
|
130,638 |
|
Distribution expenses |
|
|
19,173 |
|
- |
|
|
35,620 |
|
- |
|
General and administrative expenses |
|
|
132,080 |
|
24,448 |
|
|
218,642 |
|
52,077 |
|
Research and development costs |
|
|
95,894 |
|
33,633 |
|
|
156,607 |
|
183,367 |
|
Total operating expenses |
|
|
309,420 |
|
124,869 |
|
|
562,681 |
|
366,192 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other items |
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,783) |
|
(2,648) |
|
|
(10,735) |
|
(4,790) |
|
|
Net loss |
|
|
(303,488) |
|
(127,517) |
|
|
(548,775) |
|
(370,982) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
|
6,477 |
|
|
(6,488) |
|
7,346 |
|
|
Comprehensive loss |
|
$ |
(303,035) |
$ |
(121,040) |
|
$ |
(555,263) |
$ |
(363,636) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.01) |
$ |
(0.00) |
|
$ |
(0.01) |
$ |
(0.01) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
55,075,636 |
|
44,282,749 |
|
|
51,139,321 |
|
44,282,749 |
The accompanying notes are an integral part of these interim consolidated financial statements.
F-3
CELL MEDX CORP.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
(EXPRESSED IN US DOLLARS)
(Unaudited)
|
|
|
|
|
|
|
Accumulated |
|
||||||
|
|
|
|
Additional |
|
|
Other |
|
||||||
|
|
Common Stock |
Paid-in |
|
Deficit |
Comprehensive |
|
|||||||
|
|
Shares |
Amount |
Capital |
Reserves |
Accumulated |
Income |
Total |
||||||
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
- |
|
|
|
||||||
|
Balance - May 31, 2018 |
44,282,749 |
$ |
44,283 |
$ |
4,916,201 |
$ |
14,400 |
$ |
(6,050,841) |
$ |
2,539 |
$ |
(1,073,418) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the six months ended November 30, 2018 |
- |
|
- |
|
- |
|
- |
|
(370,982) |
|
- |
|
(370,982) |
|
Translation to reporting currency |
- |
|
- |
|
- |
|
- |
|
- |
|
7,346 |
|
7,346 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - November 30, 2018 |
44,282,749 |
|
44,283 |
|
4,916,201 |
|
14,400 |
|
(6,421,823) |
|
9,885 |
|
(1,437,054) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued for debt |
- |
|
- |
|
193,665 |
|
- |
|
- |
|
- |
|
193,665 |
|
Net loss for the six months ended May 31, 2019 |
- |
|
- |
|
- |
|
- |
|
(534,999) |
|
- |
|
(534,999) |
|
Translation to reporting currency |
- |
|
- |
|
- |
|
- |
|
- |
|
5,829 |
|
5,829 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - May 31, 2019 |
44,282,749 |
|
44,283 |
|
5,109,866 |
|
14,400 |
|
(6,956,822) |
|
15,714 |
|
(1,772,559) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,050,000 |
|
4,050 |
|
481,950 |
|
- |
|
- |
|
- |
|
486,000 |
|
|
Shares issued on exercise of warrants |
7,482,960 |
|
7,483 |
|
366,665 |
|
- |
|
- |
|
- |
|
374,148 |
|
Net loss for the six months ended November 30, 2019 |
- |
|
- |
|
- |
|
- |
|
(548,775) |
|
- |
|
(548,775) |
|
Translation to reporting currency |
- |
|
- |
|
- |
|
- |
|
- |
|
(6,488) |
|
(6,488) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - November 30, 2019 |
55,815,709 |
$ |
55,816 |
$ |
5,958,481 |
$ |
14,400 |
$ |
(7,505,597) |
$ |
9,226 |
$ |
(1,467,674) |
The accompanying notes are an integral part of these interim consolidated financial statements.
F-4
CELL MEDX CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(EXPRESSED IN US DOLLARS)
(Unaudited)
|
|
Six months ended November 30, |
|||
|
|
2019 |
2018 |
||
|
|
|
|
||
|
Cash flows used in operating activities |
|
|
||
|
Net loss |
$ |
(548,775) |
$ |
(370,982) |
|
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
Accrued interest on notes payable |
|
10,735 |
|
4,790 |
|
Amortization |
|
813 |
|
110 |
|
Financing fees - non-cash |
|
- |
|
387 |
|
Unrealized foreign exchange |
|
(2,909) |
|
(2,788) |
|
Changes in operating assets and liabilities |
|
|
|
|
|
Inventory |
|
(3,293) |
|
(50,072) |
|
Other current assets |
|
11,849 |
|
16,823 |
|
Accounts payable |
|
58,529 |
|
75,053 |
|
Accrued liabilities |
|
2,823 |
|
(13,107) |
|
Unearned revenue |
|
(244) |
|
250,000 |
|
Due to related parties |
|
(8,898) |
|
26,352 |
|
Net cash flows used in operating activities |
|
(479,370) |
|
(63,434) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of equipment |
|
(2,463) |
|
(1,915) |
|
Net cash used in investing activities |
|
(2,463) |
|
(1,915) |
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
Advances payable |
|
15,000 |
|
28,871 |
|
Proceeds from notes payable |
|
197,650 |
|
47,004 |
|
Proceeds from subscription to shares |
|
486,000 |
|
- |
|
Net cash provided by financing activities |
|
698,650 |
|
75,875 |
|
|
|
|
|
|
|
Effects of foreign currency exchange on cash |
|
1,002 |
|
5,651 |
|
Increase in cash |
|
217,819 |
|
16,177 |
|
Cash, beginning |
|
57,172 |
|
8,200 |
|
Cash, ending |
$ |
274,991 |
$ |
24,377 |
|
|
|
|
|
|
|
Non-cash financing transactions: |
|
|
|
|
|
Exercise of warrants for debt |
$ |
374,148 |
$ |
- |
The accompanying notes are an integral part of these interim consolidated financial statements.
F-5
CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2019
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS
Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development, and commercialization of therapeutic and non-therapeutic products that promote general wellness.
Unaudited Interim Financial Statements
The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2019, included in the Company’s Annual Report on Form 10-K, filed with the SEC on September 6, 2019. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended November 30, 2019, are not necessarily indicative of the results that may be expected for the year ending May 31, 2020.
Going concern
The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2019, the Company has not achieved profitable operations and has accumulated a deficit of $7,505,597. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.
Recent accounting pronouncements
In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2016-02,“Leases” (“ASU 2016-02”). ASU 2016-02 changes current U.S. GAAP for lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods. Early application is permitted. The Company adopted the ASU 2016-02 on June 1, 2019. As of the date of these financial statements, the Company has no leasing arrangements. However, the Company is evaluating a possible impact ASU 2016-02 may have on the Company’s decision to introduce leasing options for its eBalance® devices.
F-6
NOTE 2 - RELATED PARTY TRANSACTIONS
Amounts due to related parties, other than notes payable to related parties (Note 8) at November 30, 2019, and at May 31, 2019:
|
|
November 30, 2019 |
|
May 31, 2019 |
||
|
Due to the Chief Executive Officer (“CEO”) |
$ |
97,200 |
|
$ |
75,600 |
|
Due to the Chief Financial Officer (“CFO”) |
|
20,246 |
|
|
33,507 |
|
Due to the Vice President (“VP”), Technology and Operations |
|
37,438 |
|
|
54,999 |
|
Due to the former Chief Medical Officer(1) |
|
n/a |
|
|
81,059 |
|
Due to the former CEO and director (1) |
|
n/a |
|
|
51,746 |
|
Due to the former VP, Corporate Strategy and major shareholder |
|
86,770 |
|
|
86,777 |
|
Due to related parties |
$ |
241,654 |
|
$ |
383,688 |
(1)The amounts due to former CEO and former Chief Medical Officer have been reclassified to accounts payable, as both persons were not related to the Company as at November 30, 2019.
The amounts due to related parties are unsecured, due on demand and bear no interest.
During the six-month periods ended November 30, 2019 and 2018, the Company had the following transactions with related parties:
|
|
November 30, 2019 |
|
November 30, 2018 |
||
|
Management fees incurred to the CEO |
$ |
21,600 |
|
$ |
21,600 |
|
Management fees incurred to the CFO |
|
6,000 |
|
|
6,000 |
|
Consulting fees incurred to the VP, Technology and Operations |
|
22,593 |
|
|
25,638 |
|
Interest accrued on loans from a major shareholder (Note 8) |
|
7,095 |
|
|
4,294 |
|
Total transactions with related parties |
$ |
57,288 |
|
$ |
57,532 |
NOTE 3 - INVENTORY
As at November 30, 2019, the inventory consisted of eBalance® devices and accessories held for sale valued at $46,832 (May 31, 2019 - $24,505) and work in progress, that included unfinished eBalance® devices and supplies required for manufacturing valued at $27,233 (May 31, 2019 - $48,696). In addition, the inventory included a total of $3,724 (May 31, 2019 - $Nil) associated with the eBalance® devices and accessories the Company provided to certain customers under 90- to 120-day trial periods, during which time the customers have an option to return the eBalance® devices at no charge and without obligation to purchase them.
The cost of eBalance® devices used for further research and development and for in-house observational trials is recognized as part of research and development expenses. During the six-month period ended November 30, 2019, the Company recognized $3,848 as the cost of eBalance® devices used in research and development. The cost of eBalance® devices used in marketing and advertising is recognized as part of general and administrative expenses. During the six-month period ended November 30, 2019, the Company recognized $5,358 as the cost of eBalance® devices used for marketing and advertising purposes.
NOTE 4 - OTHER CURRENT ASSETS
As at November 30, 2019, other current assets consisted of $2,528 in trade accounts receivable (May 31, 2019 - $Nil), $30,086 in prepaid expenses (May 31, 2019 - $50,331), and $14,643 in receivables associated with GST Cell MedX Canada paid on the taxable supplies (May 31, 2019 - $8,556).
F-7
NOTE 5 - EQUIPMENT
Changes in the net book value of the equipment at November 30, 2019 and May 31, 2019 are as follows:
|
|
November 30, 2019 |
|
May 31, 2019 |
||
|
Book value, beginning of the period |
$ |
1,281 |
|
$ |
- |
|
Changes during the period |
|
2,463 |
|
|
1,915 |
|
Amortization |
|
(813) |
|
|
(580) |
|
Foreign exchange |
|
26 |
|
|
(54) |
|
Book value, end of the period |
$ |
2,957 |
|
$ |
1,281 |
NOTE 6 - UNEARNED REVENUE
Changes to the unearned revenue as at November 30, 2019, and May 31, 2019:
|
|
November 30, 2019 |
|
May 31, 2019 |
||
|
Unearned revenue, beginning of the period |
$ |
307,742 |
|
$ |
51,585 |
|
Deposits on distribution rights |
|
25,000 |
|
|
250,000 |
|
Security deposits received from/(refunded to) customers |
|
(2,269) |
|
|
6,806 |
|
Security deposits recognized in sales |
|
(4,537) |
|
|
- |
|
Non-refundable deposit on distribution rights |
|
(18,438) |
|
|
- |
|
Foreign exchange |
|
352 |
|
|
(649) |
|
Unearned revenue, end of the period |
$ |
307,850 |
|
$ |
307,742 |
During the six-month period ended November 30, 2019, the Company entered into a letter of intent for the wholesale distribution rights to all Mainland China, not including Hong Kong (the “LOI”). As part of the LOI, the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000. The LOI’s term is 240 days, in which for the first 120 days the Distributor is permitted to test the eBalance® devices (the “Testing Period”). During the Testing Period, the Company agreed not to enter into any agreements for the wholesale rights to Mainland China.
The Company amortizes the non-refundable deposit received from the Distributor on a straight-line basis over the full length of the LOI. As at November 30, 2019, $18,438 was recorded as revenue from distribution rights (Note 7).
NOTE 7 - REVENUE
During the six-month period ended November 30, 2019, the Company’s revenue consisted of sales of its eBalance® devices to end-users and sale of rights to the wholesale distribution of eBalance® devices. Following are the details of revenue and associated costs:
|
|
Six months ended November 30, 2019 |
|
|
Sales of eBalance® devices |
$ |
12,100 |
|
Cost of eBalance® devices |
|
(4,485) |
|
Royalty payable |
|
(1,412) |
|
Distribution rights (Note 6) |
|
18,438 |
|
Gross margin |
$ |
24,641 |
F-8
NOTE 8 - NOTES AND ADVANCES PAYABLE
The tables below summarize the short-term loans and advances outstanding as at November 30, 2019, and May 31, 2019:
|
As at November 30, 2019 |
|||||||
|
Principal Outstanding |
Interest Rate per Annum |
|
Accrued Interest(5) |
Total Book Value |
|||
|
$ |
227,128 |
6% |
Non-convertible(1) |
$ |
5,247 |
$ |
232,375 |
|
|
6,873 |
6% |
Related party(2) |
|
107 |
|
6,980 |
|
|
35,606 |
6% |
Related party(3) |
|
552 |
|
36,158 |
|
|
88,313 |
0% |
Advances(4) |
|
-- |
|
88,313 |
|
$ |
357,920 |
|
|
$ |
5,906 |
$ |
363,826 |
|
|
|||||||
|
As at May 31, 2019 |
|||||||
|
Principal Outstanding |
Interest Rate per Annum |
|
Accrued Interest(5) |
Total Book Value |
|||
|
$ |
29,065 |
6% |
Non-convertible(1) |
$ |
1,613 |
$ |
30,678 |
|
|
114,027 |
0%-12% |
Related party(2) |
|
12,533 |
|
126,560 |
|
|
275,000 |
6% |
Related party (3) |
|
6,468 |
|
281,468 |
|
|
73,048 |
0% |
Advances(4) |
|
-- |
|
73,048 |
|
$ |
491,140 |
|
|
$ |
20,614 |
$ |
511,754 |
(1) Loans Payable
During the six-month period ended November 30, 2019, in order to support its daily operations and to secure required working capital, the Company entered into several short-term convertible loan agreements with two lenders for a total of $197,650 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly. Pursuant to the loan agreements, the lenders may convert any portion of principal and/or interest accrued thereon (the “Convertible Amount”) into restricted units of common stock in the capital of the Company on the terms and at a conversion price of the then-current private placement offering. The conversion rights were assessed to have $Nil value.
As at November 30, 2019, the Company owed a total of $232,375 (2019 - $30,678) under the 6% loan agreements, and recorded $3,620 in interest on these loans (2019 - $497).
(2) Related Party Loans Payable
On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised 2,482,960 warrants to acquire 2,482,960 shares of the Company granted in consideration for the funds Mr. Jeffs advanced to the Company during its fiscal 2019 and 2018 years. To exercise the warrants, Mr. Jeffs chose to apply $124,148, the Company owed under the demand notes payable against the purchase price of the shares (Note 9). The exercise price was first applied to $15,051 (CAD$20,019) in interest accrued on the notes payable, with the remaining $109,097 (CAD$145,110) applied to the principal. The shares were issued on September 9, 2019. As at November 30, 2019, the Company owed Mr. Jeffs $6,980 under the remaining note payable (2019 - $126,560), which continues to accumulate interest at 6% per annum compounded monthly.
During the six-month period ended November 30, 2019, the Company recorded $2,422 in interest on the loans with Mr. Jeffs. (2019 - $4,294).
(3) Unsecured Line of Credit with Related Party
On August 28, 2019, Mr. Jeffs exercised 5,000,000 warrants to acquire 5,000,000 shares of the Company granted to Mr. Jeffs in consideration for an unsecured line of credit of up to $250,000 (the “Credit Line”) dated for reference December 27, 2018. To exercise the warrants, Mr. Jeffs chose to apply $250,000, the Company owed under the Credit Line against the purchase price of the shares (Note 9). The exercise price was first applied to $10,606 in interest accrued on the balance due under the Credit Line, $25,000 was applied towards the Credit Line set-up fee, and the remaining $214,394 was applied to the principal. The shares were issued on September 9, 2019. As at November 30, 2019, the Company owed Mr. Jeffs $36,158 under the Credit Line (2019 - $281,468), which continues to accumulate interest at 6% per annum compounded monthly.
F-9
During the six-month period ended November 30, 2019, the Company recorded $4,673 in interest on principal outstanding under the Credit Line (2019 - $Nil).
(4) Advances Payable
During the six-month period ended November 30, 2019, the Company borrowed $15,000. The advances are non-interest bearing, unsecured, and payable on demand. As at November 30, 2019, a total of $88,313 (2019 - $73,048) was due and payable on account of the advances.
(5) Interest Expense
During the six-month period ended November 30, 2019, the Company recorded a total of $10,735 (2019 - $4,790) in interest expense associated with its liabilities under the notes and advances payable.
NOTE 9 - SHARE CAPITAL
On May 30, 2019, the Company announced a non-brokered private placement offering (the “2019 Offering”) set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of up to $750,000. Each Unit sold under the 2019 Offering was to consist of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on the second year anniversary of the date of issuance of the Warrant. Each Warrant was to be exercisable into one share of the Company’s common stock at $0.20 per share.
On June 24, 2019, the Company closed the first tranche of its 2019 Offering by issuing 3,950,000 Units for total gross proceeds of $474,000. On July 22, 2019, the Company closed the second tranche of the 2019 Offering by issuing 100,000 Units for total gross proceeds of $12,000.
On September 9, 2019, the Company issued 7,482,960 common shares of the Company on exercise of 7,482,960 warrants the Company granted to Mr. Jeffs in consideration for the Credit Line and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements (Note 8). To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the Credit Line and notes payable against the purchase price of the shares.
Options
The changes in the number of stock options outstanding during the six-month period ended November 30, 2019, and for the year ended May 31, 2019, are as follows:
|
|
Six months ended November 30, 2019 |
|
Year ended May 31, 2019 |
||||
|
|
Number of options |
Weighted average exercise price |
|
Number of options |
Weighted average exercise price |
||
|
Options outstanding, beginning |
7,050,000 |
$ |
0.24 |
|
9,450,000 |
$ |
0.35 |
|
Options cancelled |
-- |
$ |
n/a |
|
(2,400,000) |
$ |
0.67 |
|
Options outstanding, ending |
7,050,000 |
$ |
0.24 |
|
7,050,000 |
$ |
0.24 |
Details of options outstanding and exercisable as at November 30, 2019, are as follows:
|
Number of options outstanding and exercisable |
Exercise price |
Grant date |
Expiry date |
|
2,500,000 |
$0.05 |
November 25, 2014 |
August 26, 2020 |
|
2,500,000 |
$0.35 |
August 5, 2015 |
August 5, 2020 |
|
2,050,000 |
$0.35 |
August 24, 2017 |
August 23, 2022 |
|
7,050,000 |
$0.24 |
|
|
At November 30, 2019, the weighted average remaining contractual life of the stock options outstanding was 1.30 years.
F-10
Warrants
The changes in the number of warrants outstanding during the six-month period ended November 30, 2019, and for the year ended May 31, 2019, are as follows:
|
|
Six months ended November 30, 2019 |
|
Year ended May 31, 2019 |
|
Warrants outstanding, beginning |
20,297,565 |
|
12,814,605 |
|
Warrants issued |
4,050,000 |
|
7,482,960 |
|
Warrants exercised |
(7,482,960) |
|
-- |
|
Warrants outstanding, ending |
16,864,605 |
|
20,297,565 |
Details of warrants outstanding as at November 30, 2019, are as follows:
|
Exercise price |
Grant Date |
Number of warrants exercisable |
|
$0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021 |
March 3, 2016 |
2,000,000 |
|
$1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021 |
October 12, 2016 |
9,094,605 |
|
$1.50 during the period from October 12, 2019 to October 12, 2020 |
October 12, 2017 |
1,480,000 |
|
$1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021 |
February 7, 2018 |
240,000 |
|
$0.20 expiring on June 24, 2021 |
June 24, 2019 |
3,950,000 |
|
$0.20 expiring on July 22, 2021 |
July 22, 2019 |
100,000 |
|
|
|
16,864,605 |
At November 30, 2019, the weighted average life and exercise price of the warrants was 1.61 years and $0.89, respectively.
NOTE 10 - SUBSEQUENT EVENT
Subsequent to November 30, 2019, the Company received $20,000 under convertible notes payable, which bear interest at 6% per annum compounded monthly. At the discretion of the lenders, the balances of the notes payable may be converted to units of the Company’s common stock at the price of the then-current private placement financing.
F-11
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report.
The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2019, filed with the United States Securities and Exchange Commission (the “SEC”) on September 6, 2019.
Overview
We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our current business direction.
On November 25, 2014, we completed the acquisition of a proprietary method for the application of bioelectric signaling to treat diabetes and related ailments (the “eBalance® Technology”). With our acquisition of the eBalance® Technology, we have shifted our business direction to the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.
On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia, in anticipation of increased business activity in Canada. As of the day of this Quarterly Report on Form 10-Q the Subsidiary is engaged in manufacturing, distribution, and further development of eBalance® Technology.
Recent Corporate Developments
The following corporate developments occurred during the quarter ended November 30, 2019, and up to the date of the filing of this report:
Exercise of Warrants
On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised a total of 7,482,960 warrants to acquire 7,482,960 shares the Company granted to Mr. Jeffs in consideration for the Line of Credit and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements. To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the $250,000 Credit Line and the notes payable against the purchase price of the shares. The shares were issued on September 9, 2019.
Convertible Loan Agreements
During the quarter ended November 30, 2019, in order to support our daily operations and to secure required working capital, we entered into several short-term convertible loan agreements with two lenders for a total of $197,650 in exchange for unsecured notes payable due on demand and accumulating 6% annual interest compounded monthly. Subsequent to November 30, 2019, we advanced further $20,000 from the same lenders under substantially the same terms. Pursuant to the loan agreements, the lenders may convert any portion of principal and/or interest accrued thereon into restricted units of our common stock on the terms and at a conversion price of the then-current private placement offering.
2
eBalance® Trademark
On October 17, 2019, we announced that European Union had approved our eBalance® trademark application, and issued certificate of registration number 017997155 registering the trademark eBalance® in our name. The eBalance® trademark was also registered in the U.K., bearing the registration number UK00003345540.
The eBalance® trademark applications we filed with the Canadian Intellectual Property Office on November 14, 2017, and with the United States Patent and Trademark Office on December 11, 2017, continue to be under review.
The standard registered trademark symbol in Europe is ®. We are planning to use the designation eBalance® in our marketing efforts and for any print material until such time that Canadian and/or US trademark applications are approved.
Update on eBalanceⓇ Research and Development Progress
During the first quarter of the fiscal 2020, our Board of Directors approved commencement of a follow up study of our eBalance® device. The follow up study is being organized as a Family Practice (BC) - Observational Study (the “Study”). In order to commence the Study, which we are planning to conduct in a family practice medical clinic, we recruited Dr. Peter Eppinga, a family practice physician (MD, CCFP) licensed in the province of British Columbia, Canada, as the lead investigator in the Study.
The primary objective of the follow up Study is to further confirm safety of our eBalance® device with a secondary objective looking at baseline chronic care and complex care biometrics in a clinical family practice setting. Data from this Study will be shared with Health Canada and used to further support our application to the US FDA Premarket Notification 510(k) program to clear eBalance® for sale in the USA.
Results of Operations for the Three and Six Months ended November 30, 2019 and 2018
Our operating results for the three- and six-month periods ended November 30, 2019 and 2018, and the changes in the operating results between those periods are summarized in the table below.
|
|
Three Months Ended |
|
Six Months Ended |
|
||||||
|
|
November 30, 2019 |
November 30, 2018 |
Percentage Increase/ (Decrease) |
November 30, 2019 |
November 30, 2018 |
Percentage Increase/ (Decrease) |
||||
|
Sales |
$ |
757 |
$ |
- |
n/a |
$ |
12,100 |
$ |
- |
n/a |
|
Distribution rights |
|
9,480 |
|
- |
n/a |
|
18,438 |
|
- |
n/a |
|
Cost of goods |
|
(522) |
|
- |
n/a |
|
(5,897) |
|
- |
n/a |
|
Gross margin |
|
9,715 |
|
- |
n/a |
|
24,641 |
|
- |
n/a |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
Amortization |
|
545 |
|
110 |
395.5% |
|
813 |
|
110 |
639.1% |
|
Consulting fees |
|
61,728 |
|
66,678 |
(7.4)% |
|
150,999 |
|
130,638 |
15.6% |
|
Distribution expenses |
|
19,173 |
|
- |
n/a |
|
35,620 |
|
- |
n/a |
|
General and administrative expenses |
|
132,080 |
|
24,448 |
440.2% |
|
218,642 |
|
52,077 |
319.8% |
|
Research and development costs |
|
95,894 |
|
33,633 |
185.1% |
|
156,607 |
|
183,367 |
(14.6)% |
|
Total operating expenses |
|
309,420 |
|
124,869 |
147.8% |
|
562,681 |
|
366,192 |
53.7% |
|
Interest |
|
3,783 |
|
2,648 |
42.9% |
|
10,735 |
|
4,790 |
124.1% |
|
Net loss |
$ |
303,488 |
$ |
127,517 |
138.0% |
$ |
548,775 |
$ |
370,982 |
47.9% |
Revenues
During the three-month period ended November 30, 2019, we recognized $757 (CAD$1,000) in revenue, which consisted of sales of our eBalance® wellness devices to end-users. The cost attributed to this revenue was $522 and included $88 in royalties we accrued on the sales.
During the six-month period ended November 30, 2019, we recognized $12,100 (CAD$16,000) in revenue, which consisted of sales of our eBalance® wellness devices to end-users. The cost attributed to this revenue was $5,897 and included $3,713 in manufacturing costs of eBalance® devices, and $1,412 in royalties we accrued on the sales.
3
On June 6, 2019, we entered into a letter of intent for the wholesale distribution rights to all Mainland China, not including Hong Kong (the “LOI”). As part of the LOI the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000, of which $18,438 we recorded as revenue from distribution rights for the six-month period ended November 30, 2019 ($9,480 for the three-month period ended November 30, 2019).
We did not generate any revenue during the three- and six-month periods ended November 30, 2018.
As of the date of this report on Form 10-Q, we continue research and further development of our eBalance® Technology and devices based on this technology, we are also working towards certifying our device with Health Canada as Class II medical device, and compiling required documentation for a 510(K) premarket submission with FDA, which allows to demonstrate that the eBalance® device is at least as safe and effective as a legally marketed device available on the market, which, if the submission is approved, will allow us to start our commercial activity in the USA. Until we receive Health Canada and FDA approvals, we will only be able to sell our devices as wellness devices in Canada, which will limit our potential revenue in a foreseeable future due to a smaller market share.
Operating Expenses
During the three-month period ended November 30, 2019, our operating expenses increased by 147.8% from $124,869 incurred during the three months ended November 30, 2018, to $309,420 we incurred during the three months ended November 30, 2019. The most significant expenses during this period included $83,181 in corporate communication fees (November 30, 2018 - $1,292), $95,894 we incurred in research and development fees (November 30, 2018 - $33,633), $61,728 in consulting fees (November 30, 2018 - $66,678), $15,925 in accounting and audit fees (November 30, 2018 - recovery of $2,230), and $19,173 we incurred in distribution expenses we paid or accrued to our sales representatives.
On a year-to-date basis, the most significant changes were as follows:
·During the six-month period ended November 30, 2019, our consulting fees increased by $20,361, from $130,638 we incurred during the three-month period ended November 30, 2018, to $150,999 we incurred during the six months ended November 30, 2019. Larger consulting fees during the three-month period ended November 30, 2019, were associated with $25,000 we paid for consultation on setting up our distribution channels in China.
·Our research and development fees for the six-month period ended November 30, 2019, decreased by $26,760, from $183,367 we incurred during the six-month period ended November 30, 2018, to $156,607 we incurred during the six months ended November 30, 2019. The higher research and development fees during the six-month period ended November 30, 2018, resulted mainly from $140,460 (CAD$185,000) we incurred to Western Robotics Ltd., whom we engaged to assist us with enhancement and re-designing of our eBalance® Pro wellness devices. During the six months ended November 30, 2019, our improvements were mainly associated with integration of automated billing module and smaller updates and upgrades to the eBalance® device.
·During the six-month period ended November 30, 2019, we incurred $35,620 in distribution expenses we paid or accrued to our sales representatives, who began working on distribution of our eBalance® devices in British Columbia, Canada (November 30, 2018 - $Nil). Based on our agreements with the sales representatives, we agreed to pay CAD$350 as commission for each eBalance® device they sell. In order to allow our sales representatives to establish their customer base, we agreed to a monthly fee of CAD$5,000 payable to each sales representative for an initial term of three months, which we have a right to extend on a month-to-month basis.
·Our general and administrative fees for the six-month period ended November 30, 2019, increased by $166,565, or 319.8%, from $52,077 we incurred during the six-month period ended November 30, 2018, to $218,642 we incurred during the six months ended November 30, 2019. The largest factor that contributed to this change was associated with our expenditures on corporate communications per our services agreement with Think Ink Marketing, which resulted in $139,519 we recorded during the six-month period ended November 30, 2019, as compared to $1,778 we incurred during the six-month period ended November 30, 2018. Other factors that affected our general and administrative fees were associated with a $22,155 increase to our accounting and audit fees, which increased from $770 during the six-month period ended November 30, 2018, to $22,925 during the six-month period ended November 30, 2019, marketing
4
and advertising fees, which increased by $5,785 as opposed to not having any expenses of this type during the comparative period ended November 30, 2018, and a $3,423 increase in office expenses from $2,809 we incurred during the six months ended November 30, 2018, to $6,232 we incurred during the six months ended November 30, 2019. These increases were offset by $1,531 decrease in travel and entertainment fees, which amounted to $1,987 during the six months ended November 30, 2019, and $1,797 decrease in foreign exchange, which resulted in $540 gain for the six-month period ended November 30, 2019, as opposed to $1,257 loss for the six months ended November 30, 2018.
Other Items
During the three-month period ended November 30, 2019, we accrued $3,783 (November 30, 2018 - $2,648) in interest associated with the outstanding notes payable. On a year-to-date basis, we accrued $10,738 in interest on the outstanding notes payable (November 30, 2018 - $4,790). Of this interest, during the six-month period ended November 30, 2019, we accrued $2,422 (November 30, 2018 - $4,294) on the notes payable we issued to Mr. Jeffs, our major shareholder, and $4,673 (November 30, 2018 - $Nil) we accrued on the Credit Line with Mr. Jeffs.
Liquidity and Capital Resources
Working Capital
|
|
As at November 30, 2019 |
|
As at May 31, 2019 |
|
Percentage Change |
||
|
Current assets |
$ |
400,037 |
|
$ |
189,260 |
|
111.4% |
|
Current liabilities |
|
1,870,668 |
|
|
1,963,100 |
|
(4.7)% |
|
Working capital deficit |
$ |
(1,470,631) |
|
$ |
(1,773,840) |
|
(17.1)% |
As of November 30, 2019, we had a cash balance of $274,991, a working capital deficit of $1,470,631 and cash flows used in operations of $479,370 for the period then ended. During the six-month period ended November 30, 2019, we funded our operations with $486,000 received from our private placement financing, $15,000 we borrowed under short-term non-interest bearing advances, and $197,650 we received under convertible loan agreements accumulating interest at 6% per annum, compounded monthly, and due on demand.
We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the period ended November 30, 2019. The amount of cash we have generated from our operations to date is significantly less than our current debt obligations. There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under the outstanding notes and advances payable, or to service our other debt obligations. If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.
Cash Flows
|
|
Six months ended November 30, |
||||
|
|
2019 |
|
2018 |
||
|
Cash flows used in operating activities |
$ |
(479,370) |
|
$ |
(63,434) |
|
Cash flows used in investing activities |
|
(2,463) |
|
|
(1,915) |
|
Cash flows provided by financing activities |
|
698,650 |
|
|
75,875 |
|
Effects of foreign currency exchange on cash |
|
1,002 |
|
|
5,651 |
|
Net increase in cash during the period |
$ |
217,819 |
|
$ |
16,177 |
5
Net Cash Used in Operating Activities
Net cash used in operating activities during the six months ended November 30, 2019, was $479,370. This cash was primarily used to cover our cash operating expenses of $540,136, to increase our inventory by $3,293, and to decrease our unearned revenue and amounts due to related parties by $244 and $8,898, respectively. These uses of cash were offset by $11,849 decrease in other current assets, and by $58,529 and $2,823 increases in our accounts payable and accrued liabilities, respectively.
Net cash used in operating activities during the six months ended November 30, 2018, was $63,434. This cash was primarily used to cover our cash operating expenses of $368,483, to increase our inventory by $3,240, work in progress by $46,832, and to decrease our accrued liabilities by $13,107. These uses of cash were offset by increases in our accounts payable and amounts due to related parties of $75,053 and $26,352, respectively, by $16,823 increase to our current assets and by $250,000 increase in unearned revenue associated with a deposit we received under the LOI with Live Current Media, Inc.
Non-cash transactions
During the six-month period ended November 30, 2019, our net loss was affected by the following expenses that did not have any impact on cash used in operations:
·$10,735 (2019 - $4,790) in interest we accrued on the outstanding notes payable. Of this interest, $2,422 (2019 - $4,294) was accrued on the notes payable we issued to Mr. Jeffs, and $4,673 (2019 - $Nil) was accrued on the $250,000 Credit Line provided to us by Mr. Jeffs;
·$Nil (2019 - $387) in financing fees associated with notes payable we issued to Mr. Jeffs;
·$2,909 (2019 - $2,788) gain in unrealized foreign exchange, which resulted from fluctuations of Canadian dollar denominated transactions; and
·$813 (2019 - $110) in amortization of equipment we acquired for our manufacturing operations and for our office.
Net Cash Provided by Financing Activities
During the six-month period ended November 30, 2019, we received $197,650 under convertible loan agreements, which are payable on demand and accumulate interest at 6% per annum. At discretion of the lenders, the full amount due under the loans can be converted into the units of our common stock at the then-current price of private placement financing. In addition, we received a total of $15,000 in non-interest-bearing advances which are payable on demand. In addition to the funds received as part of debt financing, we issued 4,050,000 units of our common stock for total proceeds of $486,000. We did not incur any share-issuance costs associated with the units issued as part of the private placement financing.
Net Cash Used in Investing Activities
During the six-month period ended November 30, 2019, we purchased three laptop computers for $2,463.
During the six months ended November 30, 2018, we spent $1,915 acquiring equipment for the manufacturing of our eBalance® devices.
6
Going Concern
The notes to our unaudited interim consolidated financial statements as at November 30, 2019, disclose our uncertain ability to continue as a going concern. Our current business operations are in an early development stage and as such, we were able to generate only minimal revenue from the operations. Our research and development as well as marketing plans for the near future will require large capital expenditures, which we are planning to mitigate through equity or debt financing, or combination of both. In addition, we anticipate continuing to require upfront deposits from our potential distributors, once additional geographical distribution zones are determined.
We have accumulated a deficit of $7,505,597 since inception and increased sales will be required to fund and support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our audited consolidated financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.
Off-Balance Sheet Arrangements
None.
Critical Accounting Policies
An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.
Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure
None.
Item 3. Quantitative and Qualitative Disclosure about Market Risk
None
Item 4. Controls and Procedures
Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, 2019. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.
During the quarter ended November 30, 2019, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
7
None.
There is a high degree of risk associated with investing in our securities. Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.
The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment. We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also impair or adversely affect our business, financial condition or results of operation.
Risks Associated with our Company and our Industry
We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments. Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.
The market for devices and therapies for treating and managing diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with large pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, MediSense Inc. and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.
We are subject to numerous governmental regulations which can increase our costs of developing our eBalance® Technology and products based on this technology.
Our products may be subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that we will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.
Changes in the health care regulatory environment may adversely affect our business.
A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.
8
Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.
Competitors may claim that our Technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.
Our research and development efforts may not result in the development of commercially successful products based on our eBalance® Technology, which may hinder our profitability and future growth.
Our eBalance® Technology is currently in the research and development stage as are our planned products incorporating this technology. In order to develop commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make ongoing substantial expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.
Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations.
Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether our products under development will be launched, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.
New products and technological advances by our competitors may negatively affect our results of operations.
Our products face intense competition from our competitors. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.
Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.
Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.
9
Inability to attract and maintain key personnel may cause our business to fail.
Success depends on the acquisition of key personnel. We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants. If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.
To date we have generated only minimal revenues. If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.
To date we have generated only minimal revenues. No profits have been made to date and if we fail to make any then we may fail as a business and an investment in our common stock will be worth nothing. We have a very limited operating history and thus our progress as well as potential future success cannot be reasonably estimated. Success has yet to be proven and financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance® Technology, of which there is no assurance. We continue to face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties. Since inception, we have accumulated deficit of $7,505,597 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.
We need to acquire additional financing or our business will fail.
We must obtain additional capital or our business will fail. In order to continue development of our eBalance® Technology and to successfully carry out our planned clinical and observational trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on. We currently have no arrangements for additional financing. We may also have to borrow large sums of money that require substantial capital and interest payments.
Risks related to our stock
We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.
Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue. However, there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.
There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.
Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.
Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.
Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations. Liquidity may be low despite there being a market, making it difficult to get a return on the investment. The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.
10
Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.
The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.
Because our securities constitute "penny stocks" within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:
·contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;
·contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws;
·contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;
·contains a toll-free telephone number for inquiries on disciplinary actions;
·defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and
·contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation.
The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.
We have not paid nor anticipate paying cash dividends on our common stock.
We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history. The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:
(a)we would not be able to pay our debts as they become due in the usual course of business; or
(b)except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution.
We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business.
11
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised 7,482,960 warrants to acquire 7,482,960 shares the Company granted to Mr. Jeffs in consideration for the $250,000 Credit Line and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements. To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the Credit Line and notes payable against the purchase price of the shares. The shares were issued on September 9, 2019. The shares were issued pursuant to the provisions of Regulation S of the Act, as Mr. Jeffs is not resident of the United States and is otherwise not “U.S. Person” as that term is defined in Rule 902(k) of Regulation S of the Act.
Item 3. Defaults upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
None.
|
Exhibit |
|
|
|
Number |
|
Description of Document |
|
|
Articles of Incorporation (2) |
|
|
|
Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(5) |
|
|
|
Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.(5) |
|
|
|
Bylaws (1) |
|
|
|
Specimen Stock Certificate (1) |
|
|
|
Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6) |
|
|
|
First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(7) |
|
|
|
Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(8) |
|
|
|
Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9) |
|
|
|
Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves.(9) |
|
|
|
First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9) |
|
|
|
First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves. (9) |
|
|
|
Management Consulting Agreement dated January 13, 2015 among Cell MedX Corp., and Dr. John Sanderson, MD.(10) |
|
|
|
Stock Option Agreement dated December 12, 2014 among Cell MedX Corp. and Dr. John Sanderson, MD.(10) |
|
|
|
Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.(11) |
12
|
Exhibit |
|
|
|
Number |
|
Description of Document |
|
|
eBalance® Prototype Development Agreement dated October 1, 2015 among Cell MedX Corp., and Claudio Tassi.(12) |
|
|
|
Non-binding Letter of Intent dated December 4, 2015 to Enter into Development Agreement and License Agreement among Cell MedX Corp., Claudio Tassi, and Bioformed Aesthetic S.L.(13) |
|
|
|
Loan Agreement and Note Payable dated February 4, 2016, among Cell MedX Corp., and Tradex Capital Corp. |
|
|
|
Loan Agreement and Note Payable dated March 2, 2016, among Cell MedX Corp., and Tradex Capital Corp. |
|
|
|
Loan Agreement dated March 3, 2016 between Richard Norman Jeffs and Cell MedX Corp.(14) |
|
|
|
Loan Agreement and Note Payable dated March 10, 2016, among Cell MedX Corp., and Tradex Capital Corp.(15) |
|
|
|
Loan Agreement and Note Payable dated March 30, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16) |
|
|
|
Loan Agreement and Note Payable dated March 31, 2016 among Cell MedX Corp., and Richard N. Jeffs.(16) |
|
|
|
Loan Agreement and Note Payable dated April 29, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16) |
|
|
|
Loan Agreement and Note Payable dated June 1, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16) |
|
|
|
Loan Agreement and Note Payable dated June 2, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16) |
|
|
|
Loan Agreement and Note Payable dated June 29, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16) |
|
|
|
Loan Agreement and Note Payable dated June 30, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16) |
|
|
|
Loan Agreement and Note Payable dated August 8, 2016, among Cell MedX Corp., and Richard N. Jeffs.(16) |
|
|
|
Loan Agreement and Note Payable dated August 22, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16) |
|
|
|
Letter Agreement dated September 26, 2016, between Jean Arnett, Brad Hargreaves and Cell MedX Corp.(17) |
|
|
|
Loan Agreement and Note Payable dated January 6, 2017, among Cell MedX Corp., and Richard N. Jeffs.(18) |
|
|
|
Loan Agreement and Note Payable dated February 7, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19) |
|
|
|
Loan Agreement and Note Payable dated February 27, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19) |
|
|
|
Loan Agreement and Note Payable dated January 11, 2017, among Cell MedX Corp., and Perla Capital Inc.(19) |
|
|
|
Loan Agreement and Note Payable dated January 13, 2017, among Cell MedX Corp., and Perla Capital Inc.(19) |
|
|
|
Loan Agreement and Note Payable dated February 14, 2017, among Cell MedX Corp., and Perla Capital Inc.(19) |
|
|
|
Loan Agreement and Note Payable dated March 8, 2017, among Cell MedX Corp., and Tradex Capital Corp.(19) |
|
|
|
Loan Agreement and Note Payable dated April 18, 2017, among Cell MedX Corp., and Perla Capital Inc.(19) |
|
|
|
Loan Agreement and Note Payable dated May 5, 2017, among Cell MedX Corp., and Tradex Capital Corp.(19) |
|
|
|
Loan Agreement and Note Payable dated July 12, 2017, among Cell MedX Corp., and Richard N. Jeffs. (20) |
|
|
|
Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Yanika Silina(20) |
|
|
|
Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Da Costa Management Corp.(20) |
|
|
|
Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and John Giovanni Di Cicco (20) |
|
|
|
Product Development Agreement for eBalance® dated October 16, 2017, among Cell MedX Corp. and Western Robotics Ltd.(21) |
|
|
|
Management Consulting Agreement between Dr. Terrance Owen and Cell MedX Corp. dated effective as of December 1, 2017.(22) |
|
|
|
Loan Agreement and Note Payable dated April 5, 2018, among Cell MedX Corp., and Richard N. Jeffs. |
13
|
Exhibit |
|
|
|
Number |
|
Description of Document |
|
|
Loan Agreement and Note Payable dated May 8, 2018, among Cell MedX Corp., and Richard N. Jeffs. |
|
|
|
Intellectual Property Royalty Agreement between Cell MedX Corp. and Brek Technologies Inc., dated for reference September 6, 2018. |
|
|
|
Royalty Agreement between Cell MedX Corp. and Mr. Richard Norman Jeffs, dated for reference September 6, 2018. |
|
|
|
Letter of Intent between the Company and Live Current Media, Inc. dated for reference September 10, 2018. |
|
|
|
Loan Agreement and Note Payable dated September 13, 2018, among Cell MedX Corp., and Tradex Capital Corp. (23) |
|
|
|
Credit Line Agreement dated December 27, 2018, between Richard Norman Jeffs and Cell MedX Corp.(24) |
|
|
|
Distribution Agreement between Cell MedX Corp. and Live Current Media, Inc., dated for reference March 21, 2019. (25) |
|
|
|
Loan Agreement and Note Payable dated September 4, 2019, among Cell MedX Corp. and Longview Investment Limited |
|
|
|
Loan Agreement and Note Payable dated September 6, 2019, among Cell MedX Corp. and Rain Communications Corp. |
|
|
|
Loan Agreement and Note Payable dated September 16, 2019, among Cell MedX Corp. and Longview Investment Limited |
|
|
|
Loan Agreement and Note Payable dated September 19, 2019, among Cell MedX Corp. and Rain Communications Corp. |
|
|
|
Loan Agreement and Note Payable dated September 20, 2019, among Cell MedX Corp. and Longview Investment Limited |
|
|
|
Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Longview Investment Limited |
|
|
|
Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Rain Communications Corp. |
|
|
|
Code of Ethics(3) |
|
|
|
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
101 |
|
The following materials from this Quarterly Report on Form 10-Q for the three- and six-month periods ended November 30, 2019 and 2018 formatted in XBRL (extensible Business Reporting Language): |
|
|
|
(1) Unaudited Consolidated Balance Sheets at November 30, 2019 and as at May 31, 2019. |
|
|
|
(2) Unaudited Condensed Interim Consolidated Statements of Operations for the three- and six-month periods ended November 30, 2019 and 2018. |
|
|
|
(3) Unaudited Condensed Interim Consolidated Statement of Stockholders’ Deficit as at November 30, 2019. |
|
|
|
(4) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the six-month periods ended November 30, 2019 and 2018. |
(1)Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010
(2)Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010
(3)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with SEC on August 26, 2014
(4)Reserved
(5)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014
(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014
(7)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014
(8)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014
(9)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 3, 2014
(10)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 13, 2015
(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015
(12)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2016
(13)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 15, 2015
(14)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2016
(15)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2016
(16)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2016
14
(17)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2016
(18)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2017
(19)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 29, 2017
(20)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 17, 2017
(21)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 16, 2018
(22)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on December 5, 2017.
(23)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2019
(24)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2018
(25)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2019
15
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Cell MedX Corp. |
|
|
|
|
|
|
Date: January 14, 2020 |
By: |
/s/ Frank McEnulty |
|
|
|
Frank McEnulty |
|
|
|
Chief Executive Officer and Director |
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
Date: January 14, 2020 |
By: |
/s/Yanika Silina |
|
|
|
Yanika Silina |
|
|
|
Chief Financial Officer and Director |
|
|
|
(Principal Accounting Officer) |
16
LOAN AGREEMENT
September 4, 2019
Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$19,725 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 4, 2019.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from September 4, 2019 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
|
LENDER |
|
BORROWER |
|
Longview Investment Limited |
|
Cell MedX Corp. |
|
|
|
|
|
Per: |
|
Per: |
|
|
|
|
|
|
|
|
|
/s/ R W Donaldson |
|
/s/ Yanika Silina |
|
R W Donaldson |
|
Yanika Silina, CFO |
PROMISSORY NOTE
|
Principal Amount: USD$19,725 |
September 4, 2019 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Longview Investment Limited (the “Lender”) the sum of $19,725 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum and Admin Fee calculated from September 4, 2019 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
LOAN AGREEMENT
September 6, 2019
Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$15,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 6, 2019.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from September 6, 2019 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached for.
|
LENDER |
|
BORROWER |
|
Rain Communications Corp. |
|
Cell MedX Corp. |
|
|
|
|
|
Per: |
|
Per: |
|
|
|
|
|
|
|
|
|
/s/ Raph Biggar |
|
/s/ Yanika Silina |
|
Raph Biggar, President |
|
Yanika Silina, CFO |
PROMISSORY NOTE
|
Principal Amount: USD$15,000 |
September 6, 2019 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $15,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from September 6, 2019 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
LOAN AGREEMENT
September 16, 2019
Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$24,450 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 16, 2019.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from September 16, 2019 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
|
LENDER |
|
BORROWER |
|
Longview Investment Limited |
|
Cell MedX Corp. |
|
|
|
|
|
Per: |
|
Per: |
|
|
|
|
|
|
|
|
|
/s/ R W Donaldson |
|
/s/ Yanika Silina |
|
R W Donaldson |
|
Yanika Silina, CFO |
PROMISSORY NOTE
|
Principal Amount: USD$24,450 |
September 16, 2019 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Longview Investment Limited (the “Lender”) the sum of $24,450 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum and Admin Fee calculated from September 16, 2019 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
LOAN AGREEMENT
September 19, 2019
Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$40,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 19, 2019.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from September 19, 2019 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached for.
|
LENDER |
|
BORROWER |
|
Rain Communications Corp. |
|
Cell MedX Corp. |
|
|
|
|
|
Per: |
|
Per: |
|
|
|
|
|
|
|
|
|
/s/ Raph Biggar |
|
/s/ Yanika Silina |
|
Raph Biggar, President |
|
Yanika Silina, CFO |
PROMISSORY NOTE
|
Principal Amount: USD$40,000 |
September 19, 2019 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $40,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from September 19, 2019 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
LOAN AGREEMENT
September 20, 2019
Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$67,975 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 20, 2019.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from September 20, 2019 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
|
LENDER |
|
BORROWER |
|
Longview Investment Limited |
|
Cell MedX Corp. |
|
|
|
|
|
Per: |
|
Per: |
|
|
|
|
|
|
|
|
|
/s/ R W Donaldson |
|
/s/ Yanika Silina |
|
R W Donaldson |
|
Yanika Silina, CFO |
PROMISSORY NOTE
|
Principal Amount: USD$67,975 |
September 20, 2019 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Longview Investment Limited (the “Lender”) the sum of $67,975 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum and Admin Fee calculated from September 20, 2019 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
LOAN AGREEMENT
October 30, 2019
Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$20,500 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on October 30, 2019.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from October 30, 2019 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
|
LENDER |
|
BORROWER |
|
Longview Investment Limited |
|
Cell MedX Corp. |
|
|
|
|
|
Per: |
|
Per: |
|
|
|
|
|
|
|
|
|
/s/ R W Donaldson |
|
/s/ Yanika Silina |
|
R W Donaldson |
|
Yanika Silina, CFO |
PROMISSORY NOTE
|
Principal Amount: USD$20,500 |
October 30, 2019 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Longview Investment Limited (the “Lender”) the sum of $20,500 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum and Admin Fee calculated from October 30, 2019 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
LOAN AGREEMENT
October 30, 2019
Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on October 30, 2019.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from October 30, 2019 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached for.
|
LENDER |
|
BORROWER |
|
Rain Communications Corp. |
|
Cell MedX Corp. |
|
|
|
|
|
Per: |
|
Per: |
|
|
|
|
|
|
|
|
|
/s/ Raph Biggar |
|
/s/ Yanika Silina |
|
Raph Biggar, President |
|
Yanika Silina, CFO |
PROMISSORY NOTE
|
Principal Amount: USD$10,000 |
October 30, 2019 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $10,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from October 30, 2019 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Frank McEnulty, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2019, of Cell MedX Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: January 14, 2020
/s/ Frank McEnulty
Frank McEnulty
Chief Executive Officer
(Principal Executive Officer)
CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Yanika Silina, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2019, of Cell MedX Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: January 14, 2020
/s/ Yanika Silina
Yanika Silina
Chief Financial Officer
(Principal Accounting Officer)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: January 14, 2020
/s/ Frank McEnulty
Frank McEnulty
Chief Executive Officer
(Principal Executive Officer)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: January 14, 2020
/s/Yanika Silina
Yanika Silina
Chief Financial Officer
(Principal Accounting Officer)